Celularity Inc. provided sales guidance for the first quarter and full year 2024. For the first quarter 2024, the Company expected combined net sales of its advanced biomaterial product and biobanking businesses to be in the range of $10.25 million to $11.5 million, consisting of expected net sales for its advanced biomaterial product business in the range of $9.0 million to $10.0 million and expected net sales for its biobanking business in the range of $1.37 million to $1.50 million. For the first quarter 2024, the Company expected net sales percentage growth for its advanced biomaterial product business to be in the range of 249% to 287% and net sales percentage growth of its biobanking business to be in the low single to low double-digit range, both compared to the first quarter 2023.

For the full year 2024, the Company expected combined net sales of its advanced biomaterial product and biobanking businesses to be in the range of $50 million to $56 million, consisting of expected net sales of its advanced biomaterial product business in the range of $45.0 million to $50.0 million and expected net sales of its biobanking business in the range of $5.5 million to $6.0 million. For the full year 2024, the Company expects net sales percentage growth of its advanced biomaterial product business to be in the range of 165% to 194% and net sales percentage growth of its biobanking business to be in the in the single digit range, both compared to full year 2023.